Overview

Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)

Status:
Completed
Trial end date:
2016-07-25
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the effect of azacitidine (Vidaza) to conventional care regimens on overall survival in elderly AML patients.
Phase:
Phase 3
Details
Lead Sponsor:
Celgene
Celgene Corporation
Treatments:
Azacitidine
Cytarabine